{"id":"https://openalex.org/W2072508272","doi":"https://doi.org/10.1038/sj.bjc.6603561","title":"Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment","display_name":"Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment","publication_year":2007,"publication_date":"2007-01-01","ids":{"openalex":"https://openalex.org/W2072508272","doi":"https://doi.org/10.1038/sj.bjc.6603561","mag":"2072508272","pmid":"https://pubmed.ncbi.nlm.nih.gov/17242694","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2359988"},"language":"en","primary_location":{"id":"doi:10.1038/sj.bjc.6603561","doi":"https://doi.org/10.1038/sj.bjc.6603561","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6603561","pdf_url":"https://www.nature.com/articles/6603561.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.nature.com/articles/6603561.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004047300","display_name":"Naureen Starling","orcid":"https://orcid.org/0000-0002-1496-6792","observed_orcids":["https://orcid.org/0000-0002-1496-6792"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"N Starling","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, Surrey, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, Surrey, UK","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027151441","display_name":"DP Tilden","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D Tilden","raw_affiliation_strings":["M-TAG Limited, Lee House, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M-TAG Limited, Lee House, London, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"J White","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086951","display_name":"Merck Serono Ltd. (United Kingdom)","ror":"https://ror.org/00148fb49","country_code":"GB","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210086951"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J White","raw_affiliation_strings":["Merck Pharmaceuticals, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Pharmaceuticals, UK","institution_ids":["https://openalex.org/I4210086951"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056345420","display_name":"David Cunningham","orcid":"https://orcid.org/0000-0001-5158-1069","observed_orcids":["https://orcid.org/0000-0001-5158-1069"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"D Cunningham","raw_affiliation_strings":["Royal Marsden Hosptal, Sutton, Surrey, UK","Royal Marsden Hosptal, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hosptal, Sutton, Surrey, UK","institution_ids":["https://openalex.org/I4210121186"]},{"raw_affiliation_string":"Royal Marsden Hosptal, Sutton, UK","institution_ids":["https://openalex.org/I4210121186"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5056345420"],"corresponding_institution_ids":["https://openalex.org/I4210121186"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":{"value":5190,"currency":"USD","value_usd":5190},"fwci":19.2142,"has_fulltext":true,"cited_by_count":79,"citation_normalized_percentile":{"value":0.99029485,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"96","issue":"2","first_page":"206","last_page":"212"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9355000257492065,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9355000257492065,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0544000007212162,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.006500000134110451,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9909999966621399},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":1.0},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/second-line-chemotherapy","display_name":"second-line chemotherapy","score":0.9110000133514404},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9480000138282776},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.800000011920929},{"id":"https://openalex.org/keywords/palliative-chemotherapy","display_name":"palliative chemotherapy","score":0.6259999871253967},{"id":"https://openalex.org/keywords/drug-costs","display_name":"drug costs","score":0.5210000276565552},{"id":"https://openalex.org/keywords/health-care-utilization","display_name":"health care utilization","score":0.3880000114440918},{"id":"https://openalex.org/keywords/national-health-service","display_name":"National Health Service","score":0.6060000061988831}],"concepts":[{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.8914092183113098},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.8857917785644531},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.7948306798934937},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7788118124008179},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6720812320709229},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6568164825439453},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5519471168518066},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3217073976993561}],"mesh":[{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077146","descriptor_name":"Irinotecan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016879","descriptor_name":"Salvage Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1038/sj.bjc.6603561","doi":"https://doi.org/10.1038/sj.bjc.6603561","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6603561","pdf_url":"https://www.nature.com/articles/6603561.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2359988","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2359988","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Cancer","raw_type":"Text"},{"id":"pmid:17242694","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17242694","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of cancer","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1038/sj.bjc.6603561","doi":"https://doi.org/10.1038/sj.bjc.6603561","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6603561","pdf_url":"https://www.nature.com/articles/6603561.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2072508272.pdf","grobid_xml":"https://content.openalex.org/works/W2072508272.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W1964910962","https://openalex.org/W1968151389","https://openalex.org/W2006546370","https://openalex.org/W2017352677","https://openalex.org/W2021512329","https://openalex.org/W2060515507","https://openalex.org/W2066472254","https://openalex.org/W2075642745","https://openalex.org/W2095095509","https://openalex.org/W2096122707","https://openalex.org/W2102897408","https://openalex.org/W2121368761","https://openalex.org/W2123133140","https://openalex.org/W2128403792","https://openalex.org/W2128447158","https://openalex.org/W2133399075","https://openalex.org/W2141817518","https://openalex.org/W2142564546","https://openalex.org/W2157416388","https://openalex.org/W2158863975","https://openalex.org/W2168377135","https://openalex.org/W2270140461","https://openalex.org/W2314927739","https://openalex.org/W2396646859","https://openalex.org/W2460038169","https://openalex.org/W2554977553","https://openalex.org/W2784182245","https://openalex.org/W4238668552"],"related_works":["https://openalex.org/W7095748761","https://openalex.org/W3096220503","https://openalex.org/W2590710428","https://openalex.org/W2021959409","https://openalex.org/W2284997115","https://openalex.org/W2147718573","https://openalex.org/W2091519343","https://openalex.org/W1608665794","https://openalex.org/W2092601934","https://openalex.org/W2001611786"],"abstract_inverted_index":{"The":[0,47,161,208,227,240],"treatment":[1,89],"of":[2,45,49,57,79,127,132,164,190,265,268],"colorectal":[3],"cancer":[4],"is":[5,27,42,75,248],"rapidly":[6],"becoming":[7],"a":[8,66,76,114,266],"significant":[9],"financial":[10],"burden":[11],"to":[12,28,39,53,124,197,206,271],"health-care":[13,25,254],"systems":[14],"within":[15],"economically":[16],"developed":[17],"nations.":[18],"A":[19],"current":[20,135],"challenge":[21],"for":[22,87,141,150,176,246],"oncologists":[23],"and":[24,157,172],"payers":[26],"integrate":[29],"new,":[30],"often":[31],"high-cost,":[32],"biologic":[33],"therapies":[34],"into":[35],"clinical":[36,95,129],"practice.":[37],"Inherent":[38],"this":[40,50,257],"process":[41],"the":[43,55,88,142,153,198,263,272],"consideration":[44],"cost-effectiveness.":[46],"aim":[48],"study":[51,78,143],"was":[52,121,169,222,235],"compare":[54],"cost-effectiveness":[56],"cetuximab":[58,80,104],"plus":[59],"irinotecan":[60,111],"with":[61,103,117,167,184,201,214,218,252],"an":[62,125],"appropriate":[63],"comparator":[64,199],"from":[65,93],"National":[67],"Health":[68],"Service":[69],"(NHS)":[70],"perspective.":[71],"This":[72],"economic":[73],"evaluation":[74],"trial-based":[77],"vs":[81,134],"active/best":[82,179,219],"supportive":[83,118,180,220],"care.":[84,119,137,181],"Effectiveness":[85],"estimates":[86],"groups":[90],"were":[91,139],"modelled":[92],"key":[94],"trials.":[96],"Cunningham":[97,106],"et":[98,107],"al":[99,108],"(2004)":[100],"compared":[101,110,217,251],"cetuximab/irinotecan":[102,133,168,185,215,247],"monotherapy;":[105],"(1998)":[109],"monotherapy":[112],"in":[113,152,262],"second-line":[115],"setting":[116],"Modelling":[120],"necessary":[122],"owing":[123],"absence":[126],"head-to-head":[128],"trial":[130],"data":[131],"standard":[136,154],"Costs":[138],"calculated":[140],"drugs":[144],"received,":[145],"associated":[146],"administration,":[147],"palliative":[148],"chemotherapy":[149],"patients":[151,165,177],"care":[155,221],"arm":[156],"other":[158,253],"nonchemotherapy":[159],"resources.":[160],"discounted":[162,174],"life-expectancy":[163],"treated":[166,183,273],"0.91":[170],"life-years,":[171],"0.47":[173],"life-years":[175],"receiving":[178],"Patients":[182],"accumulated":[186],"mean":[187],"additional":[188],"costs":[189],"18":[191],"901":[192],"pounds":[193,204,225,238],"per":[194,211,230,243],"patient":[195,274],"relative":[196],"arm,":[200],"11":[202],"802":[203],"attributable":[205],"cetuximab.":[207],"incremental":[209,228,241],"cost":[210,229,242],"life-year":[212,233,244],"gained":[213,234,245],"therapy":[216],"42":[223],"975":[224],".":[226,239],"quality":[231],"adjusted":[232],"57":[236],"608":[237],"relatively":[249],"high":[250],"interventions.":[255],"However,":[256],"result":[258],"should":[259],"be":[260],"considered":[261],"context":[264],"number":[267],"factors":[269],"specific":[270],"population.":[275]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":11}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}